IRIS
BUONOMO, ANTONIO RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.252
NA - Nord America 5.049
EU - Europa 3.943
SA - Sud America 657
AF - Africa 185
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.099
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.795
SG - Singapore 2.626
RU - Federazione Russa 1.973
CN - Cina 1.311
VN - Vietnam 1.206
IT - Italia 744
BR - Brasile 518
HK - Hong Kong 432
DE - Germania 254
NL - Olanda 225
FR - Francia 197
CA - Canada 140
GB - Regno Unito 124
FI - Finlandia 123
JP - Giappone 119
IN - India 117
KR - Corea 87
BD - Bangladesh 77
IE - Irlanda 73
MX - Messico 68
ZA - Sudafrica 61
AR - Argentina 53
PL - Polonia 49
IQ - Iraq 41
CI - Costa d'Avorio 35
PH - Filippine 34
ES - Italia 33
TH - Thailandia 31
AT - Austria 29
SE - Svezia 27
EC - Ecuador 25
ID - Indonesia 23
TR - Turchia 20
EG - Egitto 19
TW - Taiwan 18
PK - Pakistan 16
MA - Marocco 15
UA - Ucraina 15
SA - Arabia Saudita 14
CO - Colombia 13
LT - Lituania 13
AE - Emirati Arabi Uniti 12
CL - Cile 12
VE - Venezuela 12
JM - Giamaica 10
UZ - Uzbekistan 10
AZ - Azerbaigian 9
KE - Kenya 9
CZ - Repubblica Ceca 8
ET - Etiopia 8
DZ - Algeria 7
AU - Australia 6
BO - Bolivia 6
CH - Svizzera 6
JO - Giordania 6
LV - Lettonia 6
BE - Belgio 5
DO - Repubblica Dominicana 5
NI - Nicaragua 5
NP - Nepal 5
PE - Perù 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
AL - Albania 4
CR - Costa Rica 4
IR - Iran 4
MK - Macedonia 4
OM - Oman 4
QA - Qatar 4
RS - Serbia 4
SV - El Salvador 4
BG - Bulgaria 3
HN - Honduras 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AO - Angola 2
CV - Capo Verde 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
KH - Cambogia 2
LU - Lussemburgo 2
LY - Libia 2
MD - Moldavia 2
MG - Madagascar 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
PT - Portogallo 2
SO - Somalia 2
Totale 16.060
Salva come PNG Salva come JPEG
Città #
Singapore 1.322
San Jose 861
Ashburn 570
Moscow 496
Hefei 421
Hong Kong 405
Ho Chi Minh City 353
Beijing 331
Chandler 294
Hanoi 270
Naples 242
Santa Clara 224
Los Angeles 206
Amsterdam 181
The Dalles 165
New York 122
Lauterbourg 120
Tokyo 107
Munich 101
Millbury 81
Seoul 73
Dallas 71
São Paulo 68
Boston 62
Des Moines 62
Da Nang 61
Napoli 61
Nanjing 54
Redondo Beach 51
Buffalo 50
Orem 48
Boardman 45
Ottawa 45
Princeton 45
Seattle 44
Frankfurt am Main 42
Haiphong 42
Turku 42
Montreal 40
Warsaw 40
Rome 38
Chicago 37
Lawrence 36
Houston 31
Johannesburg 31
Chennai 30
Council Bluffs 28
Nuremberg 28
Baghdad 26
Brooklyn 26
Wilmington 26
Denver 25
Helsinki 25
Mexico City 25
Atlanta 24
London 24
Stockholm 24
Milan 23
Poplar 22
Phoenix 19
Toronto 19
Hải Dương 18
San Francisco 18
Querétaro 16
Shenyang 16
Bangkok 15
Biên Hòa 15
Can Tho 15
Manchester 15
Nanchang 15
Washington 15
Düsseldorf 14
Rio de Janeiro 14
Dublin 13
Lappeenranta 12
Charlotte 11
Guangzhou 11
Hebei 11
Jiaxing 11
Kochi 11
Thái Nguyên 11
Tân Tiến 11
Ankara 10
Dhaka 10
New Delhi 10
Porto Alegre 10
Pozzuoli 10
Tashkent 10
Thái Bình 10
Vienna 10
Zhengzhou 10
Baku 9
Bắc Giang 9
Cairo 9
Caserta 9
City of London 9
Belo Horizonte 8
Brasília 8
Bến Tre 8
Casablanca 8
Totale 8.940
Salva come PNG Salva come JPEG
Nome #
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 190
Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study 173
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) 170
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 169
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy 169
Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves 166
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C 159
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 158
A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19 158
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 155
Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy 154
Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: Results from a prospective study 153
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study 153
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19) 153
Asunaprevir for hepatitis C: A safety evaluation 152
A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C 150
Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 150
Diabetes and COVID-19: The potential role of mTOR 149
COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study 148
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. 148
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 147
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 146
Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection 146
Investigational direct-acting antivirals in hepatitis C treatment: The latest drugs in clinical development 145
Does compulsory vaccination limit personal freedom? Ethical issues 144
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5) 142
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) 142
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 141
Vitamin D deficiency is an independent risk factor and is predictor of infections in patients affected by HCV-related liver cirrhosis 141
mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study 140
Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis 139
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. 138
A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir 138
Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients 137
Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy 137
A survey on antibiotic therapy knowledge among physicians of a tertiary care and university hospital 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 135
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study 135
Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19 135
Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: A monocentric, randomized, double-blind, placebo-controlled clinical trial 135
Beclabuvir for the treatment of hepatitis C 135
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort) 135
Bulevirtide Treatment of Hepatitis Delta Virus Infection in a Kidney Transplant Recipient: A Case Report 133
Prevalenza di infezioni da CMV, HHV-6 o EBV in bambini con disturbi dello spettro autistico. 132
Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials 132
Microbiota and hepatitis C virus in the era of direct-acting antiviral agents 131
COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy) 131
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 131
Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study 130
Prevalence of HSV1/2 congenital infection assessed through genome detection on dried blood spot in individuals with autism spectrum disorders 130
Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge 129
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
Prevalence of Pneumocystis jirovecii Colonization in Non-Critical Immunocompetent COVID-19 Patients: A Single-Center Prospective Study (JiroCOVID Study) 129
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience 129
Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience 128
Human Platelet Antigen Genotypes As Predictors of Liver Cirrhosis In Patients With Hcv Chronic Infection 128
Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage 128
The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis 128
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy 128
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 128
Central venous catheter related bloodstream infections in adult patients on home parenteral nutrition: Prevalence, predictive factors, therapeutic outcome 127
Studio sulla conoscenza dell’antibioticoterapia tra i medici di un ospedale universitario di terzo livello 126
A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients 126
Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease 126
Exposure to Varicella Zoster Virus is higher in children with autism spectrum disorder than in healthy controls. Results from a case-control study. 125
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C 125
Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection. 124
Discontinued drugs in 2012 - 2013: Hepatitis C virus infection 124
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 124
Unsolved issues in the treatment of spontaneous peritonitis in patients with cirrhosis: Nosocomial versus community-acquired infections and the role of fungi 124
A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial 124
Severe Vitamin D deficiency increases mortality among patients with liver cirrhosis regardless of the presence of HCC 122
COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study 122
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 121
Human platelet antigen 3 genotype predicts platelet count in patients with HCV infection 121
Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma 121
Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort 120
SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience 120
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy 119
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience 118
Update on the Management of Surgical Site Infections 118
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 118
Prevalence of herpes simplex virus 1 and 2 antibodies in patients with autism spectrum disorders. 117
Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection 116
Current evidence on the management of hepatitis B in pregnancy 116
Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A 116
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? 116
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series 115
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused 115
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. 115
Fecal microbiota transplantation for Clostridium difficile infection: Back to the future 115
Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature 114
Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient. 114
Prevalence and titre of antibodies to cytomegalovirus and epstein-barr virus in patients with autism spectrum disorder. 114
COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak 114
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results 114
Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study 113
Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection 113
The therapeutic potential of new investigational hepatitis C virus translation inhibitors 113
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis 112
Totale 13.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.445
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/2022479 2 4 0 4 3 21 3 19 64 44 116 199
2022/2023858 85 60 23 50 99 107 18 74 120 176 32 14
2023/2024790 25 109 131 65 64 113 8 70 18 12 90 85
2024/20254.310 137 158 16 77 104 255 415 253 291 492 1.651 461
2025/20269.160 945 727 1.059 1.031 1.599 437 1.129 442 888 601 257 45
Totale 16.346